文献速递类风湿关节炎

类风湿关节炎、改善病情抗风湿药与大骨质疏松性骨折风险:挪威HUNT研究的前瞻性数据

Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway.
PubMed 文献 · RMD Open · 2024-02-20

在挪威基于人群的HUNT研究中纳入92285名参与者,其中605例确诊类风湿关节炎,随访期间共观察9670例骨折,类风湿关节炎患者88例。与无类风湿关节炎者相比,类风湿关节炎患者骨折风险比为1.41(95%CI 1.13至1.74);使用传统合成改善病情抗风湿药者风险比1.44(95%CI 1.15至1.81),使用生物制剂改善病情抗风湿药者风险比1.19(95%CI 0.64至2.21)。

要点

  • 类风湿关节炎患者较无该病者骨折风险高40%(HR 1.41,95%CI 1.13至1.74)。
  • 使用传统合成改善病情抗风湿药者骨折风险比1.44(95%CI 1.15至1.81)。
  • 使用生物制剂改善病情抗风湿药者骨折风险比1.19(95%CI 0.64至2.21),证据较弱。

核心结论

  • 类风湿关节炎患者骨折风险较无该病者高40%。
  • 使用传统合成改善病情抗风湿药者观察到相似的骨折风险,而使用生物制剂改善病情抗风湿药者骨折风险可能略低的证据较弱。

研究设计与样本

  • 基于人群的挪威Nord-Trøndelag健康研究(HUNT)前瞻性数据,纳入92285名参与者,其中经医院记录验证的类风湿关节炎诊断605例。
  • 参与者随访至首次大骨质疏松性骨折、死亡、移居或随访结束,采用Cox回归估计骨折风险比。

主要发现

  • 随访期间共观察9670例骨折,其中类风湿关节炎患者88例。
  • 与无类风湿关节炎的参照组相比,类风湿关节炎患者骨折风险比为1.41(95%CI 1.13至1.74)。
  • 使用传统合成改善病情抗风湿药者骨折风险比为1.44(95%CI 1.15至1.81)。
  • 使用生物制剂改善病情抗风湿药者骨折风险比为1.19(95%CI 0.64至2.21),关联较弱且不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rheumatoid arthritis has been associated with increased fracture risk. New treatments have improved the course of the disease substantially, but it is not clear if this influences fracture risk. We examined if rheumatoid arthritis, overall and according to disease-modifying antirheumatic drugs (DMARDs), is associated with a risk of major osteoporotic fractures. METHODS: Overall, 92 285 participants in the population-based Nord-Trndelag Health Study (HUNT), Norway were included and linked with hospital records for a validated rheumatoid arthritis diagnosis (n=605), type of DMARD treatment and fracture diagnosis. Participants were followed up until the first major osteoporotic fracture, death, emigration or end of follow-up. Cox regression was used to estimate HRs for fractures among individuals with rheumatoid arthritis, overall and by DMARD treatment, compared with participants without rheumatoid arthritis. RESULTS: A total of 9670 fractures were observed during follow-up, of which 88 were among those with rheumatoid arthritis. Compared with the reference group of participants without rheumatoid arthritis, those with the disease had an HR of fracture of 1.41 (95% CI 1.13 to 1.74). The association was largely similar for users of csDMARDs (HR 1.44; 95% CI 1.15 to 1.81), whereas the association for bDMARD users was weaker and less precise (HR 1.19; 95% CI 0.64 to 2.21). CONCLUSION: Participants with rheumatoid arthritis had a 40% higher risk of fracture than participants without the disease. A similar fracture risk was observed for conventional synthetic DMARD use, whereas there was weak evidence that the use of biological DMARDs may be associated with a somewhat lower fracture risk.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tronstad I, Hoff M, Horn J, et al. Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway. RMD Open. 2024. PMID: 38382944. doi:10.1136/rmdopen-2023-003919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。